{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to low number of events.","groupId":"OG000","lowerLimit":"29.4","upperLimit":"NA","value":"40.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"}],"units":"Participants"}],"description":"PFS is defined as the time from the date of the first dose of study treatment to the date of disease progression using the Revised Response Criteria for Malignant Lymphoma (Cheson 2014), or death from any cause, whichever occurs first.","dispersionType":"Full Range","groups":[{"description":"Participants were treated with ibrutinib 560 mg and venetoclax (starting at 20 mg, and gradually ramped up to a target dose of 400 mg).","id":"OG000","title":"Treatment-naive Open-label Arm"}],"paramType":"MEDIAN","populationDescription":"All enrolled treatment-naïve participants","reportingStatus":"POSTED","timeFrame":"For an overall median time on study of 40.51 months","title":"Progression-free Survival (PFS) (Treatment-Naive Arm)","type":"SECONDARY","unitOfMeasure":"months"}